AI Market Access Software for Value Intelligence

The Joint Clinical Assessment is the clinical component of the EU HTA Regulation. Instead of every country reviewing the same clinical evidence separately, the clinical assessment is done once at EU level and shared across member states, which continue to decide pricing and reimbursement nationally. It began applying to new oncology medicines and advanced therapy medicinal products in January 2025, and is scheduled to extend to orphan medicines and then to all new medicines in the following years. Centivence helps teams prepare for it by keeping the underlying evidence base current and traceable.

Under the JCA, member states submit their own PICO questions — population, intervention, comparator, outcome — which are consolidated into a single scope that can span many comparators and subgroups at once, on a short response timeline. Useful software has to map the evidence base against each PICO, show where comparator or outcome data is thin, and keep every claim linked to its source so the submission can be defended. Centivence organises evidence per question in its AI Evidence Repository, with a traceable citation behind every analysis.

AI helps most where market access work is repetitive and volume-driven: screening new publications for relevance, summarising studies, tracking competitor evidence, and drafting value messages from source material. The constraint in this field is that outputs must stay tied to verifiable evidence — an answer without a citation cannot be used in a payer submission. Centivence is designed around that constraint, and its AI Value Creator generates messages only from evidence you have selected, each linked back to its source.

Most teams still rely on periodic manual literature searches, which are slow and leave gaps between reviews — competitor data or a new cost-effectiveness study can surface weeks after it was published. Continuous automated monitoring closes that gap by scanning the literature as it appears and surfacing only what is relevant to a given therapy area. The Centivence AI Evidence Finder runs that monitoring across your disease area and competitors, and flags what changes the picture.

A global value dossier is the internal reference document that consolidates the clinical, economic and humanistic evidence behind a product's value, so local affiliates can adapt it for national payer submissions. It typically covers disease burden, unmet need, efficacy and safety, comparative effectiveness, economic value and patient-reported outcomes. The hard part is keeping it current as new evidence appears, which is why Centivence stores evidence in structured, continuously updated workspaces rather than static documents.

A strong payer narrative connects each claim to specific evidence, addresses the comparators payers actually care about, and is honest about where the evidence is weaker. Narratives fail under scrutiny when claims are broader than the data supports or when the underlying source cannot be produced on request. Centivence builds narratives from a curated evidence base instead of from memory, and its gap analysis makes weak areas visible before a payer finds them.

Payer submissions, HTA dossiers and internal medical reviews all require that a claim can be traced to the exact study, section and data point behind it. Without that link, statements have to be re-verified manually, which slows down reviews and creates compliance risk. Every output Centivence produces carries its citation by default, so nothing has to be reconstructed later.

At minimum, peer-reviewed scientific literature and clinical trial registries, since those are the sources payers and HTA bodies expect claims to rest on. Teams also need to bring in their own material — internal documents, data on file, and content available through company journal subscriptions — so the full evidence base sits in one place. Centivence covers over 232 million scientific papers updated weekly and lets you query them in Find Evidence, upload your own documents, and connect company subscriptions for additional full-text access.